VPH — Valeo Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- CA$10.85m
- CA$71.52m
- CA$53.91m
- 28
- 70
- 17
- 32
Annual cashflow statement for Valeo Pharma, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2019 October 31st | 2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.62 | -4.76 | -14.2 | -25.7 | -27.8 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.427 | 1.18 | 2.59 | 8.48 | 5.27 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.746 | -2.14 | -1.41 | -11.5 | 4.22 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.31 | -5.3 | -12.3 | -28.5 | -15.7 |
| Capital Expenditures | -0.945 | -1.41 | -3.46 | -6.89 | -5.55 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.022 | 0 | — | — | — |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.923 | -1.41 | -3.46 | -6.89 | -5.55 |
| Financing Cash Flow Items | -0.513 | -0.783 | -1.63 | 34.9 | -0.297 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.55 | 9.21 | 15.1 | 55 | 6.19 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.324 | 2.5 | -0.793 | 20.5 | -15 |